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Roger J. Hajjar, MD,y Jean-Sebastien Hulot, MD, PHDzSEE PAGE 451T he use of various animal models for cardio-vascular diseases has signiﬁcantly advancedour understanding of the pathophysiology
of these diseases. In addition, these animal models
have been quite useful in testing novel treatment
strategies. However, there are inter-species differ-
ences in manifestation of certain diseases that
preclude modeling them in animals (1). Treatment
strategies that work in animal models do not always
translate into effective therapies in humans. For
this reason, there is a critical need for using human-
based cellular/tissue platforms to understand the
pathological mechanisms involved and to evaluate
efﬁcient treatments. The development of technology
that induces human adult ﬁbroblasts to revert back
to pluripotent stem cells by Yamanaka et al. (2) has
opened new avenues in disease modeling. The
induced pluripotent stem cells (iPSC) can be then
differentiated into a variety of cell types including
cardiovascular ones, as shown in Figure 1. Despite
the fact that the derived cardiovascular cells are
physiologically closer to fetal and neonatal cells, a
number of genetic disorders with cardiovascular
manifestations have been reproduced with the use
of this technology, including hypertrophic cardio-
myopathy (3), LEOPARD syndrome (a genetic syn-
drome transmitted in an autosomal dominant
manner that is named for its characteristic features:
L, lentigines on the head and neck; E, electrocardio-
gram abnormalities; O, ocular hyperteleorism [wide
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ness [sensorineural type]) (4), long QT syndrome
(LQTS) (5), cathecholaminergic polymorphic ventric-
ular tachycardia (6), arrhythmogenic right ventricular
dysplasia (7), and familial dilated cardiomyopathies
(8). Most of these studies have focused on deriving
cardiomyocytes from patient-speciﬁc iPSCs and
studying the resulting phenotype. The usual ap-
proach is to obtain ﬁbroblasts (usually skin biopsy)
from speciﬁc patients with genetic diseases, to derive
stem cells, and then to differentiate them into cardi-
omyocytes. After a number of weeks in culture, the
cardiomyocytes will develop disease features such
as abnormal contractile function, dys-regulated cal-
cium movements, altered electrical, and an increase
in hypertrophic markers and can serve as a platformto model the disease. In this issue of the Journal,
Wang et al. (9) propose a different approach in which
genetic mutations are directly introduced by genome
engineering in generic embryonic stem cells or non-
diseased iPSCs. The engineered pluripotent cells can
then be differentiated into cardiomyocytes (as shown
in Fig. 2), with the hope that they will display disease
features as compared with the un-edited cell lines
(so-called isogenic controls). This approach is sup-
ported by recent developments in site-speciﬁc
genome engineering with the use of designer nucle-
ases (molecular scissors) that cut DNA sequences
within the chromosome and then can be replaced
by another sequence template. Three different types
of molecular scissors have been developed that can
be designed to cut at speciﬁc sites: 1) zinc ﬁnger
nucleases (ZFN) (10); 2) transcription activator-like
effector nuclease (11); and 3) clustered regularly
inter-spaced short palindromic repeats (CRISPR)
(12). These designer nucleases each have unique fea-
tures, but the capability of each one to target speciﬁc
DNA sequences makes them a very useful tool for
manipulating pluripotent cells. To support this
FIGURE 1 Derivation of Pluripotent Stem Cells From Fibroblasts Through the Use of Pluripotency Factors (Oct3/4, Sox2, Klf4, and c-Myc)
The pluripotent cells can be differentiated into speciﬁc cardiovascular cells in specialized media.
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461approach, Wang et al. (9) introduced the ion channel
genes KCNQ1 and KCNH2 with dominant negative
mutations causing LQTS type 1 and type 2, respec-
tively, into both embryonic stem cells and iPSCs (9).
LQTS is a genetic-based disease disorder typiﬁed by
prolonged cardiac repolarization that leads to lethal
ventricular arrhythmias (12). More than 12 different
types of LQTS have been deﬁned, and each is caused
by mutations in a distinctive cardiac ion channel (13).
LQTS type 1 (LQTS1) is based on a mutation in the
KCNQ1 gene, which encodes the slow component ofFIGURE 2 Disease Modeling in Cardiomyocytes
Fibroblasts from affected patients can be used to induce pluripotent ce
display pathological features of the disease. Sequence-speciﬁc altering t
effector nucleases (TALENs), and the clustered regularly interspaced sho
or correct them in pluripotent and stem cells. ES ¼ embryonic stem celthe delayed rectiﬁer potassium current (IKs) channel,
and it is characterized by a prolonged action poten-
tial duration and trafﬁcking defect of the KCNQ1
channel. LQTS type 2 (LQTS2) is based on a mutation
in the hERG gene (the human Ether-à-go-go-Related
Gene) that codes for the a-subunit of the repolarizing
IKr current in the cardiac action potential. The inves-
tigators used ZFNs to place these mutated genes in
a safe site within the human chromosome 19, the
AAVS1 locus. AAVS1 is a well-validated “safe harbor”
to host the DNA fragment with expected functionlls that can be differentiated to cardiomyocytes, which will in turn
ools such as zinc ﬁnger nucleases (ZFNs), transcription activator-like
rt palindromic repeats (CRISPRs) can be used to insert mutated genes
ls; iPSC ¼ induced pluripotent stem cells.
Hajjar and Hulot J A C C V O L . 6 4 , N O . 5 , 2 0 1 4
Modeling Cardiovascular Disease A U G U S T 5 , 2 0 1 4 : 4 6 0 – 2
462(14). It has an open chromatin structure and is
transcription-competent. Most importantly, there
are no known adverse effects on the cell resulting
from the inserted DNA fragment of interest in the
AAVS1 locus (14). The investigators then derived
cardiomyocytes, which displayed characteristics
of LQTS phenotype including prolongation of the
action-potential duration, compared with the un-
edited control cells. The authors also tested pharma-
cological agents, such as a calcium channel blocker,
nifedipine, and a KATP channel opener, pinacidil,
on the derived cells. In doing so, the authors have
nicely modeled the physiological features of LQTS
types 1 and 2, and the developed cell lines can be
used to differentiate cardiomyocytes and become
test beds for novel therapeutics for LQTS.
This study offers hope that genome engineering
will allow us to study the molecular mechanisms un-
derlying the pathology of genetically based cardio-
vascular diseases in the dish. There are still a number
of improvements that are required for this technology
to be more effective in modeling cardiac disorders. In
the current study, Wang et al. (9) used a safe harbor
from where to express the mutated gene while the
normal genes were being expressed concurrently.
Molecular scissors, such as TALENs and CRISPRs, can
be used to excise the KCNQ1 and hERG genes and then,
through homologous recombination, the mutated
genes can be replaced in the same site. These tools can
also be used to make genomic replacement of a DNA
fragment at a single nucleotide position. This would
circumvent the effects of expressing the mutated gene
in a remote site (e.g., AAVS1). The cardiomyocytesderived through the use of iPSCs are in general
immature and may not represent the physiological
characteristics of adult cardiomyocytes (15). Methods
to mature these cardiomyocytes both physically and
by genetic editing are being actively studied. In
addition, tissue engineering permits the reconstruc-
tion of three-dimensional muscles, allowing a large
number of physiological parameters to be measured in
these tissues (15). Finally, genetic background can
strongly inﬂuence the clinical phenotype caused by
diseased genes. Re-introducing speciﬁc mutations in
genes of interest in a generic genome is a wonderful
approach to speed up the development of functional
genomic studies but will provide limited information
on the role of modifying and/or interacting genes.
The study by Wang et al. (9) represents an exciting
ﬁrst step in producing cardiac cells that recapitulate
LQTS by inserting the mutated genes in safe harbor
sites. It will be important to develop new methods for
reconstructing the three-dimensional design of adult
vascular and myocardial tissue to allow the mea-
surements of meaningful physiological parameters.
The future of drug discovery in cardiology will
depend not on these human models of genetically
based cardiovascular diseases but also on acquired
forms of cardiac disorders.
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